SummaryRMgm-4635
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene mutation, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31142638 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei TRAP/FlpL |
Other information parent line | This line expresses FlpL recombinase under the control of the TRAP promoter, active in the mosquito oocyst stage, and selectively excises the DNA sequence flanked by FRT sites (S. Mishra, K.A. Kumar and P. Sinnis, unpublished data). The FlpL expression cassette is introduced into the silent p230p gene locus (by GIMO transfection using line 1596cl1; RMgm-687) resulting in line 1809 (RMgm-4186). The line has been generated in Leiden and cloned in the Sinnis lab. This line does not contain a drug-selectable marker. |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Choudhary HH, Mishra S |
Name Group/Department | Division of Parasitology |
Name Institute | CSIR-Central Drug Research Institute |
City | Lucknow |
Country | India |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4635 |
Principal name | PKAc cKO |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Not different from wild type |
Liver stage | PKAc cKO sporozoites exhibit normal exocytosis and gliding motility and efficiently invade hepatocytes. PKAc cKO parasites develop and egress normally in the liver. PKAc is essential for hepatic merozoite infectivity. Mice inoculated with different doses of TRAP/FlpL merosomes became positive for blood stage parasites, whereas PKAc cKOmerosomes failed to initiate blood stage infection. Although mice inoculated with high doses of PKAc cKO merosomes became positive, they were carrying intact PKAc locus as revealed by genotyping. These results demonstrate that PKAc is not important for any stage of preerythrocytic stages, but is essential for erythrocytic stages. |
Additional remarks phenotype | Mutant/mutation This mutant has been generated by replacement of the endogenous PKAc gene by an PKAc gene with a FRTed ORF in mutant RMgm-4186 that expresses FlpL. This mutant expresses the yeast FlpL recombinase under the control of the promoter of trap and does not contain a selectable marker. The flpl gene is integrated into the silent 230p locus by double cross-over integration. (Part of)The PKAc ORF is removed from the genome by using the Flp/FRT site-specific recombination (SSR) system (see RMgm-269, RMgm-747). Removal of (part of) the FRTed ORF of PKAc has been achieved by transmission of the mutant through mosquitoes, thereby activating expression of the FlpL recombinase in sporozoites that resulted in the excision of the ORF of PKAc which was flanked by FRT sequences. Protein (function) Phenotype Other mutants
|
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0835600 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0934800 | ||||||||||||||||||||||||||
Gene product | cAMP-dependent protein kinase catalytic subunit | ||||||||||||||||||||||||||
Gene product: Alternative name | PKAc | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Short description of the mutation | The mutant contains a FRTed ORF of the PKAc locus | ||||||||||||||||||||||||||
Inducable system used | Flp/FRT | ||||||||||||||||||||||||||
Short description of the conditional mutagenesis | The ORF of PKAc is removed in the sporozoite stage by the Flp/FRT system | ||||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | unknown | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | For conditional silencing of PKAc, its intron was flirted. For this, three fragments F1, F2, and F3 having a size of (1.2 kb), (1.6 kb), and (0.53 kb) were amplified using primer pairs 1066/1067, 1068/1069, and 1070/1071, respectively. F2 was directly ligated at the EcoRV site in the p3'TRAP-hDHFR-flirted vector. The fragment F2 reverse primer (1069) also contained 12 bp of TRAP 3'UTR for the continuation of UTR function as described previously. After confirmation of correct cloning of F2, fragments F1 and F3 were cloned sequentially at SacII/NotI and PstI/KpnI sites, respectively. The integration fragment was separated from the vector backbone by digesting with SacII/KpnI and transfected into the TRAP/FlpL line; S Mishra, KA Kumar, and P Sinnis, unpublished data; RMgm-4186). | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | FlpL recombinase of yeast (FlpL) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | The FlpL coding sequence was flanked by 1.58 kb and 0.55 kb of 5′ and 3′ regulatory sequences of trap, respectively. | ||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1349800 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1335900 | ||||||||||||||||||
Gene product | thrombospondin-related anonymous protein | sporozoite surface protein 2 | ||||||||||||||||||
Gene product: Alternative name | TRAP; SSP2; SSP-2 | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1349800 | ||||||||||||||||||
Gene product | sporozoite surface protein 2 thrombospondin-related anonymous protein | ||||||||||||||||||
Gene product: Alternative name | sporozoite surface protein 2; SSP2; SSP-2 | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |